Menu
Back to User profile » Dr Norio Yasui-Furukori
Papers published by Dr Norio Yasui-Furukori:
Relationship between quality of life and restless legs syndrome among a community-dwelling population in Japan
Kubo K, Sugawara N, Kaneda A, Takahashi I, Nakamura K, Nakaji S, Yasui-Furukori N
Neuropsychiatric Disease and Treatment 2016, 12:809-815
Published Date: 12 April 2016
Dietary patterns and schizophrenia: a comparison with healthy controls
Tsuruga K, Sugawara N, Sato Y, Saito M, Furukori H, Nakagami T, Nakamura K, Takahashi I, Nakaji S, Yasui-Furukori N
Neuropsychiatric Disease and Treatment 2015, 11:1115-1120
Published Date: 22 April 2015
Possible association between moderate intellectual disability and weight gain in valproic acid–treated patients with epilepsy
Tanamachi Y, Saruwatari J, Noai M, Kamihashi R, Soraoka H, Yoshimori Y, Ogusu N, Oniki K, Yasui-Furukori N, Ishitsu T, Nakagawa K
Neuropsychiatric Disease and Treatment 2015, 11:1007-1014
Published Date: 7 April 2015
Hyperprolactinemia during antipsychotics treatment increases the level of coagulation markers
Ishioka M, Yasui-Furukori N, Sugawara N, Furukori H, Kudo S, Nakamura K
Neuropsychiatric Disease and Treatment 2015, 11:477-484
Published Date: 24 February 2015
Parental bonding and attitudes toward suicide among medical college students in Japan
Hashimoto K, Sugawara N, Tanaka O, Nakamura K, Yasui-Furukori N
Neuropsychiatric Disease and Treatment 2014, 10:2015-2020
Published Date: 23 October 2014
Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder
Aoki A, Ishiguro S, Watanabe T, Ueda M, Hayashi Y, Akiyama K, Kato K, Inoue Y, Tsuchimine S, Yasui-Furukori N, Shimoda K
Neuropsychiatric Disease and Treatment 2014, 10:1793-1798
Published Date: 18 September 2014
The Yamaguchi fox/pigeon-imitation test, a brief cognitive performance rating tool, in a community-dwelling population: normative data for Japanese subjects – a preliminary study
Ishioka M, Sugawara N, Kaneda A, Okubo N, Iwane K, Takahashi I, Yasui-Furukori N
Neuropsychiatric Disease and Treatment 2014, 10:1721-1725
Published Date: 11 September 2014
A positive correlation between serum amyloid β levels and depressive symptoms among community-dwelling elderly individuals in Japan
Tsuruga K, Sugawara N, Yasui-Furukori N, Takahashi I, Tsuchimine S, Kaneda A, Nakaji S, Nakamura K
Neuropsychiatric Disease and Treatment 2014, 10:1621-1627
Published Date: 30 August 2014
The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study
Hashimoto K, Sugawara N, Ishioka M, Nakamura K, Yasui-Furukori N
Neuropsychiatric Disease and Treatment 2014, 10:1571-1576
Published Date: 22 August 2014
The effects of electroconvulsive therapy on tardive dystonia or dyskinesia induced by psychotropic medication: a retrospective study
Yasui-Furukori N, Kikuchi A, Katagai H, Kaneko S
Neuropsychiatric Disease and Treatment 2014, 10:1209-1212
Published Date: 3 July 2014
Sex differences in the prediction of the effectiveness of paroxetine for patients with major depressive disorder identified using a receiver operating characteristic curve analysis for early response [Corrigendum]
Tomita T, Norio YF, Sato Y, Nakagami T, Tsuchimine S, Kaneda A, Kaneko S
Neuropsychiatric Disease and Treatment 2014, 10:997-998
Published Date: 5 June 2014
Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders
Saruwatari J, Nakashima H, Tsuchimine S, Nishimura M, Ogusu N, Yasui-Furukori N
Pharmacogenomics and Personalized Medicine 2014, 7:121-127
Published Date: 28 April 2014
Sex differences in the prediction of the effectiveness of paroxetine for patients with major depressive disorder identified using a receiver operating characteristic curve analysis for early response
Tomita T, Norio YF, Sato Y, Nakagami T, Tsuchimine S, Kaneda A, Kaneko S
Neuropsychiatric Disease and Treatment 2014, 10:599-606
Published Date: 8 April 2014
Comparison of predictive equations for resting energy expenditure among patients with schizophrenia in Japan
Sugawara N, Yasui-Furukori N, Tomita T, Furukori H, Kubo K, Nakagami T, Kaneko S
Neuropsychiatric Disease and Treatment 2014, 10:427-432
Published Date: 28 February 2014
Possible associations between antioxidant enzyme polymorphisms and metabolic abnormalities in patients with schizophrenia
Saruwatari J, Yasui-Furukori N, Kamihashi R, Yoshimori Y, Oniki K, Tsuchimine S, Noai M, Sato Y, Nakagami T, Sugawara N, Saito M, Fujii A, Kajiwara A, Mihara S, Ogata Y, Kaneko S, Nakagawa K
Neuropsychiatric Disease and Treatment 2013, 9:1683-1698
Published Date: 1 November 2013
Comparing the influences of age and disease on the Brief Assessment of Cognition in Schizophrenia in Japanese patients with schizophrenia
Kaneda A, Katagai T, Yasui-Furukori N
Neuropsychiatric Disease and Treatment 2013, 9:1203-1208
Published Date: 14 August 2013
Worsened hypertension control induced by aripiprazole
Yasui-Furukori N, Fujii A
Neuropsychiatric Disease and Treatment 2013, 9:505-507
Published Date: 15 April 2013
Interaction between paliperidone extended release and TS-1®, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient
Yasui-Furukori N, Hashimoto K, Kubo K, Tomita T
Neuropsychiatric Disease and Treatment 2013, 9:317-320
Published Date: 3 March 2013
Update on the development of lurasidone as a treatment for patients with acute schizophrenia
Yasui-Furukori N
Drug Design, Development and Therapy 2012, 6:107-115
Published Date: 8 May 2012
Comparative in vivo bioequivalence and in vitro dissolution of two valproic acid sustained-release formulations
Akira Fujii, Norio Yasui-Furukori, Taku Nakagami, Takenori Niioka, Manabu Saito, et al
Drug Design, Development and Therapy 2008, 2:139-144
Published Date: 11 August 2008